关于我们
Introduction Location: Home >  About Us >  Introduction

Beijing Union Pharmaceutical Factory was founded in 1958; and is a state-owned enterprise affiliated to Institute of Materia Medica Chinese Academy of Medical Sciences; integrates production, R & D and marketing; currently has more than 300 employees; is rated as Beijing & Zhongguancun high-tech enterprise, and Beijing tax credit Grade A enterprise; and is included in central state-owned capital operating budget from 2012.
       The production base of Beijing Union Pharmaceutical Factory is located in Daxing, south of Beijing, with advanced equipment and facilities, sound quality system, established production lines for bulk drugs, tablets, capsules, pills, creams, lyophilized powder for injection (anticancer drugs), and small volume injection (with antineoplastic agents). The hardware condition in the factory locates in Z-park Daxing Bio-medicine Industry Park is in line with EU standards or reaches advanced domestic level, with injections fully passing newly revised GMP certification.
       Beijing Union Pharmaceutical Factory adheres to the mission of "To survive with quality, develop with innovation, and contribute to the cause of human health", relies on the solid innovation resources and research capabilities of Institute of Materia Medica, and successfully develops many innovative drugs with initial international market launch and a large variety of leading domestic generic drugs. As one of enterprise technology centers and patent demonstration units in Beijing, in recent years the Factory assumes a number of major national drug creation special project and other technology and industrialization topics, with 26 authorized patents for invention and over 10 new products in research and approval.
       Major products of Beijing Union Pharmaceutical Factory include: anti-hepatitis drugs with chemical drug bicyclol (Beijing Famous Brand) awarded the 2nd Prize of National Science and Technology Progress Award as a representative; antineoplastic agents with the first domestic paclitaxel injection, docetaxel injection, and pemetrexed disodium for injection as representatives; and cardiovascular drugs with the first domestic felodipine tablets as a representative. The Factory employs marketing strategy based on academic promotion, not only with products covering the whole country, but opening international markets with quality advantages. Bicyclol, DDB Pills, and Ftibamzone cream have landed Ukraine, Kazakhstan, Uzbekistan, Republic of Korea, Myanmar and other countries, creating excellent economic benefits.
       In the next three to five years, Beijing Union Pharmaceutical Factory will be committed to concentrated and innovative development, maintain a positive and stable operation, build "innovative drug production, study and research base" in collaboration with the Institute of Materia Medica, master a number of key technologies, achieve a number of R & D results, and highlight the main theme of "Created in China" in pharmaceutical industry.